Guillaume Charpentier

Suggest Changes
Learn More
BACKGROUND Many patients with poorly controlled type 2 diabetes mellitus (DM) receive, as initial insulin treatment, the addition of a basal formulation to an existing regimen of oral antidiabetic(More)